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responsibility of XAbstract Simple, rapid and speciﬁc liquid chromatography–mass spectrometry (LC–MS) methods
have been developed and validated for the quantiﬁcation of cefcapene acid in human plasma and
urine. Plasma samples were simply pretreated with methanol for deproteinization. Urine samples
were brieﬂy diluted with methanol–water (50:50, v/v), and centrifuged to remove large particles.
Chromatographic separation was performed on a Hedera ODS-2 column. For the plasma assay,
the isocratic mobile phase consisted of 35% solvent A (Methanol) and 65% solvent B (10 mM
ammonium acetate buffer solution containing 0.2% folic acid) with a ﬂow rate of 0.3 mL/min.
For the urine assay, the isocratic mobile phase consisted of 30% solvent A (Methanol) and 70%
solvent B (10 mM ammonium acetate buffer solution containing 0.2% folic acid) with a ﬂow rate of
0.3 mL/min. The assays were linear over the concentration ranges of 0.03–5 mg/mL in plasma and
0.1–400 mg/mL in urine, and were successfully applied to a pharmacokinetic study after single and
multiple oral administrations of cefcapene pivoxil hydrochloride tablets in healthy Chinese
volunteers.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
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m (L. Ding).
i’an Jiaotong University.1. Introduction
Cefcapene pivoxil (S-1108), an oral cephem antibiotic posses-
sing a pivaloyloxymethyl ester group, is a prodrug of cefca-
pene acid (S-1006) [1,2]. It is easily deesteriﬁed in the intestine
in a manner similar to that of other prodrugs having a
pivaloyloxymethyl (POM) ester [3–5]. Its active metabolite,
cefcapene acid (see Fig. 1), is highly active against a widelsevier B.V. All rights reserved.
Fig. 1 The chemical structures of cefcapene pivoxil and its active metabolite cefcapene acid (A) and the chemical structure of
cefalexin (B).
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several bacteria such as Pseudomonas aeruginosa and
Enterococci. No publication described the method for the
analysis of cefcapene pivoxil in human. By immediately
adding potassium ﬂuoride (4 mol/L, 20 mL) and 0.5% folic
acid (20 mL) to 200 mL freshly collected plasma, we have
solved the problem of instability of cefcapene pivoxil in
plasma. Although the method with a lower limit of quantiﬁca-
tion (LLOQ) of 0.01 mg/mL for the determination of cefcapene
pivoxil in human plasma was developed in our laboratory, we
still cannot detect cefcapene pivoxil in the freshly collected
incurred human plasma. This result implied that the deester-
iﬁcation of cefcapene pivoxil in the intestine was rapid and
almost complete. There are a few reports which described the
pharmacokinetics of cefcapene acid determined by microbio-
logical assay method [6–9] or isotope labeling method [10].
The major drawback of microbiological assay is the lack of
speciﬁcity. At the same time, isotope labeling cannot be used
in human. Nakashima et al. [11] described an HPLC-UV
method for the analysis of cefcapene acid in human, in which
solid phase extraction must be used in sample preparation. In
this paper, we describe two simple, rapid and speciﬁc liquid
chromatography–mass spectrometry (LC–MS) methods with
the LLOQs of 0.03 mg/mL for the determination of cefcapene
acid in human plasma and 0.1 mg/mL in human urine, respec-
tively. The fully validated methods have been successfully applied
to a pharmacokinetic study of cefcapene acid in health Chinese
volunteers receiving single oral doses at 50, 100 and 200 mg of
cefcapene pivoxil hydrochloride tablets, as well as multiple oral
doses of 100 mg t.i.d. for 7 consecutive days.2. Experimental
2.1. Chemicals and reagents
The reference standard of cefcapene acid (purity 94.0%, lot
no.101101) was supplied by Shandong Luoxin Pharmaceutical
group Co. Ltd. (Shandong, China). The internal standard
(cefalexin, the IS) was purchased from National Institute forthe Control of Pharmaceutical and Biological Products (purity
94.4%, lot no.130408-200710; NICBP, Beijing, China).
Methanol of HPLC grade was purchased from Merck KGaA
(Darmstadt, German). Ammonium acetate and formic acid
were of analytical grade purity and purchased from Nanjing
Chemical Reagent Co. Ltd (Nanjing, China). Distilled water
was used throughout the study.2.2. Instrumentation
An Agilent series 1100 LC/MSD VL system was used,
consisting of a binary pump, a vacuum degasser, a thermo-
static column oven, an autosampler and a single quadrupole
mass spectrometer (Agilent Technologies, Palo Alto, CA,
USA). An electrospray ionization (ESI) interface in positive
ionization mode was used. Data processing was performed
with ChemStation software (version 10.02 A).2.3. Chromatographic and mass spectrometric conditions
A Hedera ODS-2 column, 5 mm, 150 mm 2.1 mm i.d.
(Hanbon Science and Technology) with a security Guard– C18
(4 mm 2.0 mm, 5 mm, Phenomenex) was used for the analyte
separation. For the plasma assay, the isocratic mobile phase
consisted of 35% solvent A (Methanol) and 65% solvent B
(10 mm ammonium acetate buffer solution containing 0.2%
folic acid). The ﬂow rate was set at 0.3 mL/min. For the urine
assay, the isocratic mobile phase consisted of 30% solvent A
(Methanol) and 70% solvent B (10 mM ammonium acetate
buffer solution containing 0.2% folic acid). The ﬂow rate
was also set at 0.3 mL/min. Chromatography was performed
at 35 1C using a 6 mL injection volume.
The mass spectrometer equipped with a ESI source was set
with a drying gas (N2) ﬂow of 13 L/min, nebulizer pressure of
40 psi, drying gas temperature of 350 1C, capillary voltage of
4.0 kV and fragmentor voltage of 125 V. Positive ion mode
was employed. Quantitation was carried out in selected ion
monitoring (SIM) mode, using target ions at m/z 454.2 for
cefcapene acid and m/z 348.2 for the IS.
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samples
Primary stock solutions of cefcapene acid (1.0 mg/mL) and
cefalexin (1.0 mg/mL) were prepared in methanol. A series of
cefcapene acid standard working solutions ranging from 1 to
100 mg/mL were obtained by further dilution of the stock
solution with methanol. The working solutions of cefalexin for
the internal standard were also prepared by diluting aliquots
of stock solution with methanol. All standard solutions were
stored at 20 1C and were brought to room temperature
before use.
Calibration standard and quality control (QC) samples in
plasma and urine were prepared by diluting corresponding
working solutions with drug-free human plasma and urine,
respectively. The concentrations of calibration standard were
0.03, 0.1, 0.3, 0.7, 1.5, 3, 5 mg/mL for plasma and 0.1, 0.3, 1, 3,
10, 30, 100, 200, 400 mg/mL for urine, respectively. The
concentrations of QC samples were 0.08, 0.6, 4 mg/mL for
plasma and 0.2, 20, 350 mg/mL for urine, respectively. All the
plasma and urine samples were stored at 80 1C.
2.5. Sample preparation
2.5.1. Sample preparation for plasma
Aliquot of 0.2 mL plasma sample was added with 10 mL IS
solution (10 mg/mL). After a thorough vortex mixing for 30 s,
the mixture was deproteinized with 600 mL methanol and
centrifuged at 16,000 r/min for 5 min. Aliquot of 6 mL of the
supernatant liquid was injected into the LC–MS system for
analysis.
2.5.2. Sample preparation for urine
Aliquot of 0.1 mL urine sample was added with 25 mL IS solution
(100 mg/mL). After a thorough vortex mixing for 30 s, the mixture
was diluted with 900 mL methanol–water (50:50, v/v), vortex-
mixed for 30 s, and centrifuged at 16,000 r/min for 3 min. Aliquot
of 6 mL of the supernatant liquid was injected into the LC–MS
system for analysis.
2.6. Method validation
The methods were validated for speciﬁcity, linearity, precision,
accuracy, extraction recovery, matrix effect and stability
according to the US Food and Drug Administration (FDA)
[12] and Chinese State Food and Drug Administration
(SFDA) [13] guidance for validation of bioanalytical methods.
2.6.1. Selectivity
The selectivity was assessed by comparing the chromatograms
of six different sources of blank biological samples with the
corresponding spiked samples. Each blank sample was tested
for interferences using the proposed extraction procedure and
LC–MS conditions.
2.6.2. Linearity and LLOQ
The linearity was evaluated by assaying calibration curves in
biological samples on three consecutive batches. The curves
were ﬁtted by a weighted (1/x2) least-squares linear regression
method through the measurement of the peak area ratios of
the analyte to the IS. The acceptance criterion for a calibrationcurve was a correlation coefﬁcient (r) of 0.99 or more, and that
each back-calculated standard concentration must be within
15% deviation from the nominal value except at the LLOQ,
for which the maximum acceptable deviation was set at 20%.
The LLOQ was deﬁned as the lowest concentration in the
standard curve at which precision and accuracy should fall
within the range of 80–120%. It was established by using ﬁve
samples independent of standards.
2.6.3. Precision and accuracy
The QC samples were prepared and analyzed on three separate
analytical batches to evaluate the accuracy and intra- and
inter-day precisions of the analytical method. The accuracy
and precisions of the method were determined by analyzing
ﬁve replicates of the QC samples along with one standard
curve on each of three batches. Assay precision was calculated
as the relative standard deviation (RSD, %) by use of one-way
analysis of variance. The accuracy is the degree of closeness of
the determined value to the nominal true value under the
prescribed conditions. Accuracy is deﬁned as the relative
deviation of the value (E) of a standard from that of its true
value (T) expressed as a percentage (RE%). It was calculated
using the formula RE%¼ (ET)/T 100. Intra- and inter-
day precisions were required to be less than 15%, and the
accuracy to be within 715%.
2.6.4. Extraction recovery
The extraction recovery of cefcapene acid was evaluated by
analyzing ﬁve replicates at QC levels. The recovery was
calculated by comparison of the peak areas of cefcapene acid
extracted from biological samples with those obtained from
the pure standard without the procedure of extraction.
2.6.5. Matrix effect
The matrix effect is due to co-elution of some endogenous
components present in biological samples. These components
may not give a signal in SRM of target analytes, but can certainly
decrease or increase the response of analytes dramatically to
affect the sensitivity, accuracy and precision of the method. Thus
assessment of matrix effect constitutes an important and integral
part of validation for quantitative LC–MS method for the
supporting pharmacokinetic studies [14]. The potential for a
matrix effect was evaluated by comparing the peak areas obtained
from the analytes added to the reconstituted solutions obtained
from blank biological samples, which originated from ﬁve
different donors and were submitted to the sample-preparation
process (A), with those obtained from the analytes dissolved in
mobile phase (B). QC samples were evaluated by analyzing ﬁve
samples at each level. The matrix effect was calculated using the
formula matrix effect (%)¼A/B 100%. The matrix effect at
every concentration level should be less than 15%.
2.6.6. Stability
Stability tests were designed to assess the stability of the
analytes under the conditions expected during handling of
clinical samples. The stability of cefcapene acid in plasma and
urine was studied under a variety of storage and handling
conditions by analysis of replicates (n¼3) of QC samples. The
short-term temperature stability was tested by storing the QC
samples at ambient temperature for hours. Freeze–thaw stability
(80 1C) was checked through three freeze and thaw cycles.
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was conducted by reanalyzing the extracted QC samples
kept under the autosampler conditions (8 1C) for hours. The
long-term stability was assessed after storage at 80 1C for
weeks. The stabilities of the stock solution of cefcapene acid and
the IS were determined by placing the stock solution at 20 1C
for 2 months. The results were compared with the freshly
prepared solutions.
2.6.7. Diluting study
Five replicate plasma samples (8 mg/mL) were prepared and
double diluted with blank plasma. Then the plasma samples
were submitted to the sample-preparation process. The per-
cent deviations of accuracy and precision were within710%.
If the concentration levels of plasma samples exceeded the
range of standard calibration curve, we would dilute the
samples following the diluting study.
2.7. Pharmacokinetic study
2.7.1. Subjects
The established methods were applied in a pharmacokinetic study
performed in healthy Chinese subjects. Twelve healthy volunteers
(6 males and 6 females, mean age, 34.873.2 years; mean weight,
60.972.7 kg; mean height, 166.674.8 cm) were enrolled in this
study in Xijing Hospital afﬁliated to the Fourth Military Medical
University, China. The volunteers were free of cardiac, hepatic,
renal, pulmonary, neurologic, gastrointestinal and hematologic
diseases, as assessed by physical examination, electrocardiography
and the laboratory tests including hematology, biochemistry,
electrolytes, urinalysis. All the subjects were instructed to abstain
from taking any medication for 2 weeks before and during the
whole study period. The study protocol was approved by the local
Ethical Review Committee in accordance with the principles of the
Declaration of Helsinki and the recommendations of the State
Food and Drug Administration of China. Written informed
consent was obtained from all the subjects.
Each volunteer participated in three phases: phases A, B
and C, and there was a 7-day washout period between phases.
In phases A and B, 12 volunteers received 50 mg and 200 mg
of cefcapene pivoxil hydrochloride tablets at 8:00 am after a
standard breakfast, respectively. In phase C, 12 volunteers
received 100 mg of cefcapene pivoxil hydrochloride tablet at
8:00 am after a standard breakfast on day 1, and were
administered cefcapene pivoxil hydrochloride tablets 100 mg
three times a day for 7 days (days 2–8).
In phases A, B and C (day 1), venous blood samples were
drawn pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4,5, 6, 8
and 10 h post-dose. In phase C (days 2–8), venous blood
samples were drawn before drug administration on days 5, 6
and 7 to determine the Cmin-ss. On day 8, venous blood
samples were drawn at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8
and 10 h post-dose.
Urine samples were collected in phase C (day 1) in the
following time segments: 0–2, 2–4, 4–6, 6–8, 8–12 and 12–24 h
post-dose. All samples were stored at 80 1C.
2.7.2. Pharmacokinetic analysis
The data analysis of pharmacokinetic parameters was per-
formed by using Drug and Statistics software (Version. 2.0,
Chinese). Non-compartmental pharmacokinetic parameters werecalculated for cefcapene acid. The maximum plasma concentration
(Cmax) and the time to attain it (Tmax) were noted directly.
The area under the plasma concentration–time curve from time
zero to the last measurable concentration (AUC0–t) was calculated
using the linear trapezoidal rule and was extrapolated to inﬁnity
(AUC0–N) according to the relationship AUC¼(AUC0–tþCt)/
Ke. Ct is the last concentration evaluated in plasma which is
greater than the lower limit of quantiﬁcation (LLOQ) and the
elimination rate (Ke) was calculated by linear regression of the
terminal points of the semi-log plot of plasma concentration
against time. The half-life (t1/2) and CL/F were calculated based
on the following equations: t1/2¼0.693/ Ke; CL/F¼KeVc. Vc is
the apparent volume of distribution of the center compartment,
which was estimated by the model after calculation. Vd/F was
the apparent volume of distribution, and MRT was mean
residence time.3. Results and discussion
3.1. Conditions for chromatography
Cefalexin was chosen as the internal standard because its
chemical properties and mass spectral fragmentation were similar
to those of cefcapene acid. When selecting the mobile phase for
HPLC–MS system, attention was paid to the inﬂuence of mobile
phase on the chromatographic retention and the MS sensitivity.
Using 10 mM concentration of ammonium acetate buffer, the
chromatographic peaks became sharp and symmetrical. More-
over, formic acid could improve the ionization efﬁciency.
Different concentrations of formic acid at levels of 0.05, 0.1,
0.2 and 0.3% were tested in the aqueous portion of the mobile
phase. The results showed that adding 0.2% formic acid in the
aqueous portion was sufﬁcient to achieve the highest MS
sensitivity for cefcapene acid and the IS. Finally, acceptable
retention time and separation of cefcapene acid were obtained
using the following mobile phase: for plasma, an elution system
of methanol-10 mM ammonium acetate buffer containing 0.2%
formic acid (35:65, v/v) with a ﬂow rate of 0.3 mL/min; for urine,
an elution system of methanol-10 mM ammonium acetate buffer
containing 0.2% formic acid (30:70, v/v) with a ﬂow rate of
0.3 mL/min.
3.2. Conditions for ESI–MS
Due to amino and carboxylic groups in its chemical structure,
cefcapene acid had mass spectrometric response either in the
positive ion mode or in the negative ion mode. The test result
showed that the signal intensity of the analyte obtained in the
positive mode was much higher than that in the negative
mode. So, the positive monitoring mode was selected in the
MS detection. The protonated molecular ion [MþH]þ at m/z
454.2 was selected as the target ion for cefcapene acid.
Comparing with capillary voltage, desolvation gas (drying
gas) ﬂow and temperature, fragmentor voltage is considered to
be the most important instrumental parameter in the optimi-
zation of ionization settings [15,16]. The intensity of this ion
was compared at fragmentor voltages of 70, 90, 100, 120, 140
and 160 V. The result showed that the highest sensitivity was
obtained using a fragmentor voltage of 120 V. More detailed
optimizing was conducted at fragmentor voltages of 115, 120,
125, 130 and 135 V. The result showed that the highest
Fig. 2 Mass spectra of the positive ions of cefcapene acid
(A) and cefalexin (B) at 125 V fragmentor voltage.
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Therefore, a fragmentor voltage of 125 V was used to carry
out LC–ESI–MS in the SIM mode. At this fragmentor voltage
the most intensive ion of the IS was the ion [MþH]þ at m/z
348.2. Therefore, the positive ion [MþH]þ at m/z 348.2 was
selected as the target ion for the IS (see Fig. 2).3.3. Sample preparation
In the method for determination of cefcapene acid in human
plasma, the plasma sample was precipitated with methanol
and then the extracts were injected into the mobile phase
stream without evaporation and reconstitution. It could
simplify the sample preparation procedure signiﬁcantly and
also meet the requirements of the assay. No interference was
observed from any endogenous or exogenous plasma matrix.Fig. 3 Typical SIM chromatograms obtained from (A) blank
plasma sample, (B) plasma spiked with cefcapene acid at the
LLOQ level (0.03 mg/mL) and with the IS, and (C) plasma
obtained from a Chinese volunteer 0.75 h after oral administra-
tion of 50 mg cefcapene pivoxil hydrochloride tablet.3.4. Selectivity
Selectivity was assessed by comparing the chromatograms of
drug-free human plasma and urine with the corresponding
spiked plasma and urine, for the test of endogenous inter-
ferences. For plasma, observed retention time for cefcapene
acid and the IS was 2.5 and 3.2 min, respectively. For urine,
observed retention time for cefcapene acid and the IS was 2.9
and 3.9 min, respectively. The typical chromatograms of theplasma and urine blank samples are shown in Figs. 3(A) and
4(A). No peak of the endogenous substances was observed,
which would interfere with the detection of cefcapene acid and
the IS. Figs. 3(B) and 4(B) show the chromatograms of spiked
plasma and urine samples with cefcapene acid at LLOQ level
and the IS. Typical chromatograms of plasma and urine
samples are shown in Figs. 3(C) and 4(C), which were
collected 0.75 h after oral administration of a single dose of
50 mg cefcapene pivoxil hydrochloride tablet for plasma and
Fig. 4 Typical SIM chromatograms obtained from (A) blank
urine sample, (B) urine spiked with cefcapene acid at the LLOQ
level (0.1 mg/mL) and with the IS, and (C) urine obtained from a
Chinese volunteer 2–4 h after oral administration of 100 mg
cefcapene pivoxil hydrochloride tablet.
Table 1 Precision and accuracy of the LC–MS method to
determine cefcapene acid in human plasma and urine (in
three analysis batch, ﬁve replicates for each batch).
Sample Concentration
(mg/mL)
RSD (%) RE (%)
Added Found Intra-
batch
Inter-
batch
Accuracy
Plasma 0.08672 0.08381 2.6 9.4 3.4
0.6504 0.6440 4.0 13.1 1.0
4.336 4.352 1.6 9.6 0.4
Urine 0.2172 0.2209 10.4 6.0 1.7
21.72 21.66 10.8 6.0 0.4
380.1 401.2 8.0 3.1 5.4
Table 2 Results of extraction recovery of cefcapene acid
in human plasma and urine (n¼5).
Sample Concentration
(mg/mL)
Recovery (%) RSD (%)
Added Found
Plasma 0.08672 0.07926 91.4 3.1
0.6504 0.6393 98.3 1.5
4.336 4.349 100.3 4.3
Urine 0.2172 0.2131 98.1 6.9
21.72 20.40 93.9 4.4
380.1 380.0 99.7 0.9
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cefcapene pivoxil hydrochloride tablet for urine, respectively.
The corresponding concentrations of cefcapene acid in plasma
and urine were found to be 0.6458 and 108.0 mg/mL,
respectively.
3.5. Linearity and LLOQ
The validated assays were linear in the range from 0.03 to
5 mg/mL for plasma and from 0.1 to 400 mg/mL for urine,
respectively. The typical calibration curves of cefcapene acid in
human plasma and urine were Y¼0.7390Cþ0.009650 and
Y¼0.01315Cþ0.0004304, respectively, with both coefﬁcients
of correlation (r) about 0.999. The lowest concentration ofdetermination with RSDo20% was taken as the LLOQ which
was found to be 0.03 mg/mL for plasma and 0.1 mg/mL for
urine. In all the cases, the calculated concentrations in the
calibration curves were within 715% bias from the nominal
value except at the LLOQ, which was set at 720%.
3.6. Precision and accuracy
Table 1 summarizes the intra- and inter-day precision and
accuracy for cefcapene acid evaluated by assaying the QC samples.
The precision was calculated using one-way ANOVA. The results
demonstrated that the values were within the acceptable range and
the methods were accurate and precise [17].
3.7. Recovery and matrix effect
The observed value of extraction recovery of the methods
from plasma and urine and %RSD (n¼5) are shown in
Table 2. Recoveries were more than 80% at different QC
concentrations for both plasma and urine with acceptable
variability.
Matrix interferences caused by plasma and urine endogen-
ous materials were evaluated by comparing the peak areas of
the post-spiked standards with those of the neat standards at
the QC concentrations, the ratio was within the acceptable
limits (85–115%). No signiﬁcant ion suppression or enhance-
ment was observed at the expected retention time of the
targeted ions.
Table 3 Summary of stability of cefcapene acid in human plasma under different storage conditions
(n¼3).
Storage condition Concentration (mg/mL) RSD (%) RE (%)
Added Found
Room temperature for 3.5 h 0.08672 0.08363 3.2 3.6
0.6504 0.6811 3.2 4.7
4.336 4.507 7.4 3.9
Three freeze–thaw cycles 0.08672 0.08896 4.3 2.6
0.6504 0.6984 2.0 7.4
4.336 4.368 2.6 0.7
Freezing for 10 weeks at 80 1C 0.08672 0.09359 1.5 7.9
0.6504 0.6301 4.1 3.1
4.336 3.958 5.3 8.7
Autosampler for 9.5 h at 8 1C 0.08672 0.08525 4.3 1.7
0.6504 0.7188 0.7 10.5
4.336 4.426 5.3 2.1
Table 4 Summary of stability of cefcapene acid in human urine under different storage conditions
(n¼3).
Storage condition Concentration (mg/mL) RSD (%) RE (%)
Added Found
Room temperature for 3 h 0.2172 0.2170 3.4 0.1
21.72 22.11 9.8 1.8
380.1 384.9 0.9 1.3
Three freeze-–thaw cycles 0.2172 0.2074 5.6 4.6
21.72 20.03 1.1 8.2
380.1 401.6 0.3 5.2
Freezing for 7 weeks at 80 1C 0.2172 0.2062 1.2 5.1
21.72 20.41 2.6 6.0
380.1 380.4 2.7 0.1
Autosampler for 7.5 h at 8 1C 0.2172 0.2216 6.2 2.0
21.72 21.80 8.9 0.3
380.1 422.1 1.7 11.0
Fig. 5 The mean plasma concentration–time curves of cefcapene
acid in healthy Chinese volunteers (n¼12) after single oral
administration of 50, 100 and 200 mg cefcapene pivoxil hydro-
chloride tablet, respectively.
Fig. 6 The mean urinary recovery–time curve of cefcapene acid
in healthy Chinese volunteers (n¼12) after single oral adminis-
trations of 100 mg cefcapene pivoxil hydrochloride tablet.
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Table 5 The main pharmacokinetic parameters for cefcapene acid after single and multiple oral administration cefcapene pivoxil
hydrochloride tablets in healthy Chinese volunteers. (mean7SD, n¼12).
Parameters Single-dose administration Multiple-dose administration
50 mg 100 mg 200 mg 100 mg
Cmax (mg/mL) 1.20870.346 2.84670.588 4.79871.421 2.46670.627
AUC0–10 (mg h/mL) 3.56070.941 8.92471.907 16.9374.71 6.79271.723
AUC0–N (mg h/mL) 3.65970.949 9.01771.889 17.0574.73 6.89171.722
AUCss – – – 6.77371.708
t1/2 (h) 1.070.1 1.070.1 1.170.1 1.070.2
Tmax (h) 1.770.3 2.270.5 2.570.5 1.770.4
MRT0–10 (h) 2.570.2 2.970.2 3.370.3 2.470.3
CL/F (L/h) 14.7474.83 11.6372.92 12.8274.63 15.1073.55
Vd/F (L) 20.7275.87 17.3375.96 20.6878.72 21.1575.75
Fig. 7 The mean (7SD) plasma concentration–time curves of
cefcapene acid in healthy Chinese volunteers (n¼12) after multi-
ple oral administrations of 100 mg cefcapene pivoxil hydro-
chloride tablets.
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The results obtained from determination of stability (Tables 3
and 4) showed no signiﬁcant degradation occurred under the
conditions tested. The plasma samples were stable at ambient
temperature for 3.5 h, during three freeze–thaw cycles, and at
80 1C for 10 weeks. The urine samples were stable at ambient
temperature for 3 h, during three freeze–thaw cycles, and at
80 1C for 7 weeks. The stock solutions of cefcapene acid and
the IS in methanol were observed to remain stable for 1 month at
20 1C.3.9. Application of the method in pharmacokinetic studies
3.9.1. Single-dose pharmacokinetics
All the 12 enrolled subjects participated in three phases of the
PK study. The mean plasma concentration–time curves of
cefcapene acid after a single oral dose of 50, 100 and 200 mg
are shown in Fig. 5, and the pharmacokinetic parameters are
summarized in Table 5. Over the dose range studied, the mean
Cmax, AUC0–t and AUC0–N increased linearly across the doses
by linear regression analysis. Dose proportionality was
observed (P40.05) by the analysis of ANOVA on the valuesof ln(Cmax/dose) and ln(AUC/dose) among the three dose
groups. Thus, Cmax and AUC proved to be dose proportional
across the studied doses by different methods. The value of
Tmax increased slightly with dose escalation. The values of t1/2,
CL/F and Vd/F were independent of dose (P40.05). The Cmax
and AUC were higher than literature reported [5] which
indicated that cefcapene pivoxil hydrochloride tablets may
exist racial difference.
The urinary recovery of cefcapene acid versus time after oral
administration of the drug to the human subjects is shown in
Fig. 6. The cumulated rate of cefcapene acid excreted in urine was
60.1%,which is also higher than literature reported [6].
3.9.2. Multiple-dose pharmacokinetics
The 12 subjects received 100 mg cefcapene pivoxil hydrochloride
tablets thrice daily for 7 days. The mean plasma concentration–
time curves of cefcapene acid after the ﬁrst dose (day 1) and the
last dose (day 7) are presented in Fig. 7, and the pharmacokinetic
parameters from the non-compartmental analysis of measured
plasma concentrations on day 1 and day 7 are provided in
Table 5. Mean (SD) plasma concentrations (Cmin-ss) on the 4th,
5th, 6th, and 7th days before dosing were 0.08108 (0.03988),
0.1022 (0.03782), 0.07065 (0.03098) and 0.09925 (0.04501) mg/mL,
respectively. No signiﬁcant difference in Cmin-ss was found by
ANOVA analysis, indicating that steady state was achieved after
administration of 100 mg cefcapene pivoxil hydrochloride tablets
for 7 consecutive days. Under steady state conditions, cefcapene
acid was absorbed with the median Tmax of 1.7 h and a mean Cmax
of 2.466 mg/mL. And cefcapene acid cleared from plasma with no
signiﬁcant difference of t1/2 between the ﬁrst and the last dose. But,
the mean AUC values were lower in multiple-dosing regimen than
the corresponding values obtained after single-dose (day 1)
administration, and no accumulation was found following repeat
dosing of cefcapene acid with Rac of 0.76 for AUC0–10. A high DF
of cefcapene acid in plasma was achieved at 2.8.4. Conclusion
The simple, rapid and speciﬁc LC–ESI–MS methods for quanti-
ﬁcation of cefcapene acid in human plasma and urine have been
developed and validated. There were no signiﬁcant interferences
from endogenous compounds. The fully validated methods have
been successfully applied to the pharmacokinetics in health
Chinese volunteers.
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